Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice
- 1 September 1988
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 12 (1) , 59-66
- https://doi.org/10.1007/bf01805741
Abstract
Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigenesis and uterine adenomyosis in SHN virgin mice. Mice received a subcutaneous pellet of MPA every 2 months: I) during the limited period of 1–3 months of age; II) throughout the experiment beginning at 6–8 months of age; and III) throughout the experiment beginning at 2–3 months of age. All treatments significantly enhanced mammary tumorigenesis with little difference in the effects among treatments. The progression of uterine adenomyosis was also stimulated in Experiments I and III, but not in Experiment II. These results are in good accord with our previous observations with progesterone, indicating that MPA has progesterone-like effects on mammary and uterine lesions of mice.This publication has 20 references indexed in Scilit:
- Effects of different schedules of progesterone treatment on mammary tumorigenesis and uterine adenomyosis in SHN virgin miceLife Sciences, 1987
- Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALBc female miceCancer Letters, 1986
- Enhancement of spontaneous mammary tumorigenesis at advanced age in mice by temporary stimulation of mammary growth during youthLife Sciences, 1986
- Oral medroxyprogesterone in the treatment of metastatic breast cancerJournal of Surgical Oncology, 1986
- Inhibition by medroxyprogesterone acetate of precancerous mammary hyperplastic alveolar nodule formation in miceBreast Cancer Research and Treatment, 1985
- Alteration of the development of mammary hyperplastic alveolar nodules and uterine adenomyosis in SHN mice by different schedules of treatment with CB-154Acta Endocrinologica, 1984
- Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in ratsEuropean Journal of Cancer and Clinical Oncology, 1984
- ADVANCED BREAST CANCER: RESPONSE TO HIGH DOSE ORAL MEDROXYPROGESTERONE ACETATEAustralian and New Zealand Journal of Medicine, 1984
- The induction of adenomyosis in mice by intrauterine pituitary isograftsLife Sciences, 1981
- Relative importance of genotype and type of mammary tumor virus on mammary tumorigenesis in micePublished by Elsevier ,1977